Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Dalteparin	5000 IU (International Units) dalteparin in 0.2 mL (milliliters) subcutaneously once a day (Arm A)
Unfractionated Heparin	5000 IU unfractionated Heparin (UFH) in 5 mL subcutaneously 3 times a day (Arm B) for 6 to 14 days.

Participant Flow:   Overall Study

	Dalteparin	Unfractionated Heparin
STARTED	42	42
Received Treatment	41[1]	42
COMPLETED	39	36
NOT COMPLETED	3	6
Death	0	1
Adverse Event	0	3
unknown	0	2
Withdrawal by Subject	2	0
Protocol Violation	1	0

Reporting Groups

	Description
Dalteparin	5000 IU dalteparin in 0.2 mL subcutaneously once a day (Arm A)
Unfractionated Heparin	5000 IU unfractionated Heparin (UFH) in 5 mL subcutaneously 3 times a day (Arm B) for 6 to 14 days.

Baseline Measures

	Dalteparin	Unfractionated Heparin	Total
Number of Participants   [units: participants]	41	42	83
Age   [units: years] Mean ± Standard Deviation	61.7 ± 10.6	60.8 ± 10.9	61.3 ± 10.7
Gender   [units: participants]
Female	18	21	39
Male	23	21	44

1.  Primary:

Confirmed Thromboembolic Events   [ Day 21 ]

2.  Primary:

Composite of Objectively Verified Thromboembolic Events   [ Day 21 ]

3.  Secondary:

All Cause Mortality   [ Day 14, Day 21 (End of Study) ]

4.  Secondary:

Stroke - Ischemic or Hemorrhagic   [ Day 21 ]

5.  Secondary:

Bleeding - Major or Minor   [ Day 21 ]

6.  Secondary:

Allergic Reactions (Drug-related)   [ Day 21 ]

7.  Secondary:

Thrombocytopenia   [ Day 21 ]